Today: 10 June 2026
Nvidia stock (NVDA) heads into CES week after Friday rebound as SEC filing flags planned insider sale
4 January 2026
2 mins read

Nvidia stock (NVDA) heads into CES week after Friday rebound as SEC filing flags planned insider sale

NEW YORK, January 4, 2026, 09:31 ET — Market closed

  • Nvidia shares closed up 1.26% at $188.85 on Friday, with chip stocks leading the first session of 2026.
  • A Form 144 filing showed Nvidia officer Donald F. Robertson Jr. plans to sell up to 80,000 shares under a 10b5-1 plan.
  • Traders are watching CEO Jensen Huang’s CES appearance on Jan. 5 and U.S. jobs data on Jan. 9 for the next catalyst.

Nvidia (NVDA) shares closed up 1.26% at $188.85 on Friday, a firm start to 2026 as chip stocks led a rebound in U.S. equities. The stock traded between $188.26 and $192.93 and saw roughly 148 million shares change hands.

The move matters because Nvidia remains a bellwether for risk appetite in semiconductors, and early-January positioning can set the tone for the quarter. With the company’s heavy weight in major indexes, small swings often ripple into the broader AI-linked trade.

Investors now face a narrow window of catalysts that can reset sentiment quickly. CEO Jensen Huang is due to speak at CES this week, while key U.S. economic reports could shift the outlook for interest rates — a sensitive input for high-growth stocks.

On Friday, the Philadelphia Semiconductor Index — a gauge of major U.S. chipmakers — jumped 4%, helping offset weakness in some megacap tech names that kept broader index gains in check. “Buy the dip, sell the rip,” is still the mindset, said Joe Mazzola, head of trading and derivatives strategy at Charles Schwab. Reuters

A fresh regulatory filing also landed before markets closed for the weekend. A Form 144 filed with the U.S. Securities and Exchange Commission on Jan. 2 showed Nvidia officer Donald F. Robertson Jr. intends to sell up to 80,000 shares, with an estimated market value of about $14.9 million.

The filing described the transaction as a Rule 10b5-1 sale through Morgan Stanley Smith Barney. A 10b5-1 plan is a pre-set trading instruction that lets insiders sell shares on a schedule, designed to reduce the risk of trading on nonpublic information.

Form 144 is a notice used when insiders plan to sell restricted or “control” securities, and it can precede sales that later appear in Form 4 filings. Investors typically watch whether selling is routine or clusters around turning points in the stock.

Beyond the filing, attention shifts to Las Vegas. Nvidia says Huang will deliver a CES presentation scheduled to start at 1 p.m. PT (4 p.m. ET) on Monday at Fontainebleau Las Vegas, and the company plans a run of demos tied to AI and robotics during the show.

Macro data may matter just as much for the group. The U.S. employment report due Jan. 9 is expected to show payrolls up 55,000 and unemployment at 4.6%, while consumer price index data are due Jan. 13, according to a Reuters poll and calendar.

But a stronger jobs report or hotter inflation print could push Treasury yields higher and pressure richly valued chip stocks, particularly those tied to AI spending. The first wave of fourth-quarter guidance across corporate America could also reset expectations for data-center demand.

Traders will also keep an eye on the $190 area after Friday’s close just below it, a level that often acts as a psychological pivot. A clean break above it could invite momentum buying, while a slip back into the mid-$180s would test whether the early-year bounce has staying power.

Markets reopen Monday, with Huang’s CES appearance landing at the U.S. close and Friday’s jobs report the key macro hurdle. Nvidia’s next earnings report is scheduled for Feb. 25 after the close, according to Wall Street Horizon.

Stock Market Today

  • Outlook Therapeutics Shares Jump 26% on FDA Fast-Track Review for Lytenava
    June 10, 2026, 5:57 PM EDT. Outlook Therapeutics shares surged about 26% to $0.89 on heavy volume as the FDA designated its Lytenava (ONS-5010) resubmission a Class 1 review, triggering a faster 60-day decision timeline. The drug targets wet age-related macular degeneration (wet AMD), a vision-impairing condition. The FDA's ruling follows an appeal overturning earlier efficacy concerns and reclassifies the application for expedited review. Despite the stock's gains, Outlook remains below the $1 Nasdaq compliance threshold, raising concerns over dilution. CEO Bob Jahr called the update a testament to the company's strong application. Lytenava, an anti-VEGF therapy, would compete with Roche and Regeneron products in the lucrative U.S. wet AMD market.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
MARA stock jumps 10% as bitcoin miners rebound — what traders watch before Monday
Previous Story

MARA stock jumps 10% as bitcoin miners rebound — what traders watch before Monday

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings
Next Story

Eli Lilly stock ends higher to start 2026 as traders eye JPM conference, earnings

Go toTop